Insider Buying: Celsion Co. (NASDAQ:CLSN) Director Buys 5,000 Shares of Stock

Celsion Co. (NASDAQ:CLSN – Get Rating) Director Frederick J. Fritz acquired 5,000 shares of the stock in a transaction that occurred on Friday, April 8th. The stock was acquired at an average cost of $4.05 per share, for a total transaction of $20,250.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of CLSN traded down $0.35 during midday trading on Monday, hitting $3.57. The company had a trading volume of 7,001 shares, compared to its average volume of 262,678. The company’s 50 day moving average price is $5.43 and its 200 day moving average price is $9.00. The stock has a market cap of $20.60 million, a price-to-earnings ratio of -0.94 and a beta of 2.11. Celsion Co. has a 52 week low of $3.90 and a 52 week high of $23.25. The company has a quick ratio of 7.67, a current ratio of 7.67 and a debt-to-equity ratio of 0.10.

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC boosted its stake in Celsion by 181.8% during the 3rd quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 23,261 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Celsion in the 4th quarter worth approximately $35,000. Two Sigma Advisers LP acquired a new stake in shares of Celsion in the 3rd quarter worth approximately $68,000. Virtu Financial LLC bought a new stake in shares of Celsion in the 4th quarter worth approximately $55,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Celsion in the 4th quarter worth approximately $59,000. 10.75% of the stock is owned by hedge funds and other institutional investors.

Separately, StockNews.com started coverage on shares of Celsion in a research report on Monday. They issued a “hold” rating on the stock.

About Celsion (Get Rating)

Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies.

Recommended Stories